ATE283065T1 - Mehrzweckvakzine gegen umhüllte viren - Google Patents

Mehrzweckvakzine gegen umhüllte viren

Info

Publication number
ATE283065T1
ATE283065T1 AT96913123T AT96913123T ATE283065T1 AT E283065 T1 ATE283065 T1 AT E283065T1 AT 96913123 T AT96913123 T AT 96913123T AT 96913123 T AT96913123 T AT 96913123T AT E283065 T1 ATE283065 T1 AT E283065T1
Authority
AT
Austria
Prior art keywords
mhc molecules
vaccine compositions
virus
vaccine against
cells
Prior art date
Application number
AT96913123T
Other languages
English (en)
Inventor
Donald L Morton
Original Assignee
Wayne John Cancer Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wayne John Cancer Inst filed Critical Wayne John Cancer Inst
Application granted granted Critical
Publication of ATE283065T1 publication Critical patent/ATE283065T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A61K39/001114—CD74, Ii, MHC class II invariant chain or MHC class II gamma chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT96913123T 1995-04-24 1996-04-24 Mehrzweckvakzine gegen umhüllte viren ATE283065T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/427,034 US6168787B1 (en) 1995-04-24 1995-04-24 Pluripotent vaccine against enveloped viruses
PCT/US1996/005731 WO1996033734A1 (en) 1995-04-24 1996-04-24 A pluripotent vaccine against enveloped viruses

Publications (1)

Publication Number Publication Date
ATE283065T1 true ATE283065T1 (de) 2004-12-15

Family

ID=23693219

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96913123T ATE283065T1 (de) 1995-04-24 1996-04-24 Mehrzweckvakzine gegen umhüllte viren

Country Status (8)

Country Link
US (2) US6168787B1 (de)
EP (1) EP0830140B1 (de)
JP (1) JPH11509521A (de)
AT (1) ATE283065T1 (de)
AU (1) AU708327B2 (de)
CA (1) CA2219339A1 (de)
DE (1) DE69633919T2 (de)
WO (1) WO1996033734A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19626614A1 (de) * 1996-07-02 1998-01-08 Immuno Ag Komplex aus Antigen und Zellbestandteil, Impfstoffzusammensetzung, welche den Komplex enthält, pharmazeutische Präparation sowie Verfahren zur Herstellung des Komplexes
US6093693A (en) * 1996-11-18 2000-07-25 The Wellesley Hospital Foundation B cell activation
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6656471B1 (en) 1998-11-17 2003-12-02 Board Of Regents, The University Of Texas System HIV-specific T-cell induction
US20070128209A1 (en) * 2005-03-21 2007-06-07 Network Immunology Inc. Vaccine based method for protection against hiv infection
US20060211012A1 (en) * 2005-03-21 2006-09-21 Network Immunology Inc. Mhc class ii as a preventive vaccine against hiv infection
EP2010216A4 (de) * 2006-03-24 2010-06-09 Donald L Morton Mykobakterielle immuntherapie für krebsbehandlung
WO2009016433A2 (en) * 2006-09-15 2009-02-05 Ottawa Health Research Institute Oncolytic rhabdovirus
WO2008083203A1 (en) * 2006-12-28 2008-07-10 Saint Louis University Identification of multivalent viral envelope protein epitopes

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5030621A (en) * 1987-04-23 1991-07-09 Bystryn Jean Claude Shed melanoma antigen compositions
US5840317A (en) * 1989-11-03 1998-11-24 Morton; Donald L. Composition comprising tumor cell lines containing GD2 ganglioside GM2 ganglioside, M-TAA, and either M-urinary antigen or M-fetal antigen
US5882654A (en) * 1989-11-03 1999-03-16 Morton; Donald L. Polyvalent melanoma vaccine
GB9201023D0 (en) 1992-01-17 1992-03-11 Medical Res Council Vaccines
US5651993A (en) 1992-11-18 1997-07-29 Yale University Specific immune system modulation
US6218166B1 (en) * 1994-12-09 2001-04-17 John Wayne Cancer Institute Adjuvant incorporation into antigen carrying cells: compositions and methods

Also Published As

Publication number Publication date
JPH11509521A (ja) 1999-08-24
EP0830140A1 (de) 1998-03-25
AU708327B2 (en) 1999-08-05
DE69633919D1 (de) 2004-12-30
AU5573196A (en) 1996-11-18
CA2219339A1 (en) 1996-10-31
EP0830140B1 (de) 2004-11-24
WO1996033734A1 (en) 1996-10-31
US20030185806A1 (en) 2003-10-02
DE69633919T2 (de) 2005-12-01
US6168787B1 (en) 2001-01-02

Similar Documents

Publication Publication Date Title
ATE295895T1 (de) Genetischer impfstoff gegen den immunschwäche virus
Wiktor Cell-mediated immunity and postexposure protection from rabies by inactivated vaccines of tissue culture origin
CY1115749T1 (el) Κυκλοϊος χοιρων, νουκλεϊνικα οξεα, πολυπεπτιδια και εμβολια
NO963508L (no) Urease-basert vaksine og behandling av Helicobacter-infeksjon
ATE149841T1 (de) Impfstoffe gegen krebs und infektionskrankheiten
DE69637642D1 (de) Und kombinierte zusammensetzungen und deren verwendung
BR0107857A (pt) Proteìnas compreendendo regiões conservadas de antìgeno nhha de superfìcie de neisseria meningitidis
EA199800746A1 (ru) Способ генерации противовирусного иммунного ответа у человека или животного
EP0584266A4 (de) Karcinoembryonale antigen expremierende rekombinante viren und methoden ihrer anwendung.
DE60117978D1 (de) Modifizierung des hepatitis b kernantigens
IS4703A (is) Þáttur er örvar griplufrumur
EP0841941A4 (de) Neuartige nicht pyrogene bakterienstämme und ihre verwendung
EP0835315A4 (de) Impstoff gegen den für die atemwegs- und reproduktionserkrankungen beim schwein verantwortlichen virus
ATE362379T1 (de) Induktion rev- und tat-spezifischer zytotoxischer t-zellen zur prävention und behandlung einer infektion durch humanen immundefizienz-virus (hiv)
DE60119734D1 (de) Hpv-e7 zur behandlung von menschlichem papillomavirus
DE60110822D1 (de) Zubereitung zur immunisierung gegen den aids-virus
FI102382B1 (fi) Ilmentämisjärjestelmä ihmisen respiratory syncytial -viruksen glykoproteiinien immunogeenisia fragmentteja sisältäviä kimeerisiä glykoproteiineja varten
ATE312920T1 (de) Dna immunisierung gegen chlamydia infektion
ATE105334T1 (de) Schimaerische glykoproteine enthaltende immunogenische abschnitte von menschlichem parainfluenzavirus typ 3.
ATE283065T1 (de) Mehrzweckvakzine gegen umhüllte viren
ATE355375T1 (de) Bakterioferritin aus helicobacter pylori
ATE101200T1 (de) Impfstoffe gegen menschliche respiratorische viren.
Karpenko et al. Results of phase I clinical trials of a combined vaccine against HIV-1 based on synthetic polyepitope immunogens
Naveed et al. Immune modulatory potential of anti-idiotype antibodies as a surrogate of foot-and-mouth disease virus antigen
ATE494377T1 (de) Vakzine gegen ipnv die aus hefezellen isoliert werden

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties